CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,…
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include…
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce…
Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of…
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the…
Generative AI advances claim efficiency and accuracyFORT WORTH, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Advancements in artificial intelligence (AI)…
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human…
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for…
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and…